---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009596"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:08:44.234633+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# InspireMD Q4 revenue down 20.6% YoY; net loss widens to $4.8M; resumes CGuard shipments under MDD

## Summary
- Q4 CGuard revenue $1.026M (-20.6% YoY) due to temporary CE Mark expiration; full year revenue $5.123M (+18.9%).
- Net loss Q4 $4.845M ($0.60/share) vs $4.097M ($0.53) in Q4 2021; full year net loss $18.491M ($2.35/share).
- Cash and equivalents $17.8M at Dec 31, 2022, down from $34.0M a year ago.
- Resumed CGuard shipments to CE Mark territories in mid-March 2023 under MDD; expects MDR recertification in coming weeks.
- US IDE trial enrollment on track to complete by end of Q2 2023; 20 sites currently enrolling.

## SEC filing metadata
- accession: 0001493152-23-009596
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315223009596/0001493152-23-009596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315223009596/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009596
- JSON: https://secwatch.observer/filing/0001493152-23-009596.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009596.txt

## Key facts
- Earnings Releases
  InspireMD, Inc. reported fourth quarter ended December 31, 2022 results: revenue $1,026,000, net income Net loss for the fourth quarter of 2022 totaled $4,845,000, or $0.60 per basic and diluted share, EPS $0.60 per basic and diluted share.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: $1,026,000
  - Net income: Net loss for the fourth quarter of 2022 totaled $4,845,000, or $0.60 per basic and diluted share
  - EPS: $0.60 per basic and diluted share
  - Result: reported results
  source text: and operating results for the fourth quarter ended December 31, 2022. Fourth Quarter 2022 and Recent Developments : ● Generated CGuard revenues for the fourth quarter 2022 of $1,026,000, a 20.6% decrease from $1,291,000 for the fourth quarter of 2021. The decrease was caused by reduced shipments due to the temporary expiration of the Company’s CE Mark for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1433607/000149315223009596/0001493152-23-009596-index.htm
- Earnings Releases
  InspireMD, Inc. reported the year ended December 31, 2022 results: revenue $5,171,000.
  - Period: the year ended December 31, 2022
  - Revenue: $5,171,000
  - Result: reported results
  source text: For the twelve months ended December 31, 2022, total revenue increased by $676,000, or 15.0%, to $5,171,000, from $4,495,000 during the twelve months ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1433607/000149315223009596/0001493152-23-009596-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.